Charles Bieberich
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Charles Bieberich is a Professor at the University of Maryland Baltimore County, USA. His research primarily focuses on the reactivation of tumor suppressors and the application of mRNA nanoparticles to enhance antitumor immunity. Recent articles contribute to the understanding of cancer biology and therapeutic interventions in preclinical models.
Recent Grants
Grant: Close
Mild hyperthermia to enhance delivery of therapeutic nanocarriers in tumors: imaging, in vivo study, and simulation
Open Date: 2017-09-01
Close Date: 2020-08-31
Grant: Close
Developing a strategy to identify & validate pharmacodynamic kinase inhibitor biomarkers
Open Date: 2016-01-04
Close Date: 2018-12-31
Grant: Close
MYC RNAi-PT Combination Nanotherapy for Metastatic Prostate Cancer Treatment
Open Date: 2013-10-01
Close Date: 2014-09-01
Grant: Close
Role of TRPA1 & TRPV1 in pain and voiding symptoms in a new mouse CP/CPPS model
Open Date: 2013-09-27
Close Date: 2015-09-26
Grant: Close
MicroCT Imaging Based Theoretical Simulation and Protocol Design in Magnetic Nanoparticle Hyperthermia
Open Date: 2013-09-01
Close Date: 2017-08-31
Articles (11)
Barcode plots for ‘Ribosome Biogenesis’, ‘Cytoplasmic Translation’, and ‘tRNA Processing’ pathways in PIN samples. All three pathways are positively enriched in MYC-PIN and BMPC-PIN samples, and negatively enriched in PTEN-Null PIN samples.
Year:
2026
Volcano plots for PTEN-Null PIN, MYC-PIN, and BMPC-PIN compared to their respective wild-type lobes with differentially expressed genes (yellow), CCP score genes (labeled), and genes in proliferation associated GO-BP pathways (blue) mitotic spindle organization (A), cell division (B), chromosome segregation (C), DNA replication (D), G2/M transition mitotic cytokinesis (E), and cell cycle (F). (G) Volcano plots depicting the top PC1 genes that drove enrichment of the proliferation associated GO-BP pathways in A-F (blue).
Year:
2026
Differential expression analysis of MYC PIN samples compared to FVB, and GSEA. Leading edge genes from GSEA using 'Dang MYC Bound' gene set for MYC PIN, BMPC PIN, and BMPC Primary samples compared with FVB samples.
Year:
2026
GSEA enrichment plots of the 20 gene sets with highest (positive enrichment) and lowest (negative enrichment) normalized enrichment scores for Pten-Null PIN, MYC-PIN, and BMPC-PIN compared to their FVB counterparts.
Year:
2026
Wild-type FVB, MYC-PIN, PTEN-Null PIN, BMPC-PIN, and BMPC primary tissue stained with H&E, and IHC staining for PTEN and phospho-AKT. Positive phospho-AKT staining in the epithelium of FVB and PIN samples is concordant with negative staining for PTEN. All tumor cells stain positively for phospho-AKT and negatively for PTEN.
Year:
2026
IHC staining for RPS2 in wild-type FVB, PTEN-Null PIN, MYCPIN,and BMPC-PIN, and antibody validation. A-B) PIN lesions with PTEN loss have decreased epithelial RPS2 compared to wild-type luminal epithelial cells. C-D) Higher power view of A and B. E-H) PIN lesions with MYC overexpression (MYC PIN [E-F] and BMPC PIN) have increased RPS2 staining, with the strongest staining observed in BMPC PIN [G-H]. I) Western blot from prostate cancer cell lines shows RPS2 antibody specificity by western blot analysis by showing a single band at the predicted molecular weight (37 kDa). Beta-Actin was used as a loading control.
Year:
2026
Prostate cancer ranges from indolent to rapidly progressive. An elevated cell proliferation index portends poor outcomes, yet the molecular alterations essential for increased cell proliferation remain ill-defined. Gain of MYC combined with biallelic PTEN loss predicts prostate cancer mortality. Prior studies have shown that combined MYC overexpression and Pten loss, driven by the Hoxb13 locus, results in prostatic intraepithelial neoplastic (PIN) lesions that progress to metastatic disease (BMPC mice). Yet, single gene alterations in these mice result only in PIN lesions. In this study, we performed transcriptomic profiling of PIN lesions from each of the three genotypes. Whereas MYC alone resulted in increases in genes related to cell-cycle regulation/cell division, combined MYC and Pten loss led to a further and more consistent increase and a synergistic cell-cycle progression. Increased ribosome biogenesis/translation is required for cell proliferation. Whereas MYC alone increased 45S rRNA and most components of the translation machinery, these were more strongly induced in BMPC mice. Surprisingly, Pten loss alone resulted in a downregulation of translation machinery genes, which could explain the absence of biallelic PTEN loss in human PIN lesions and early carcinomas. Some MYC targets were increased only after Pten loss, indicating Pten loss increases MYC activity. Implications: Increased cell cycle and translational machinery gene induction may explain the synergy between MYC and PTEN loss for increasing prostate cancer cell proliferation and disease aggressiveness. These results provide further support for the therapeutic targeting of translation in prostate cancer.
Year:
2026
Gene expression across five translation-related pathways for Pten-Null PIN samples is comparable to or less than wild-type samples, and expression increases in MYC-PIN and BMPC-PIN, with expression of some genes increasing even higher in primary and metastatic samples.
Year:
2026
Prostate cancer ranges from indolent to rapidly progressive. An elevated cell proliferation index portends poor outcomes, yet the molecular alterations essential for increased cell proliferation remain ill-defined. Gain of MYC combined with biallelic PTEN loss predicts prostate cancer mortality. Prior studies have shown that combined MYC overexpression and Pten loss, driven by the Hoxb13 locus, results in prostatic intraepithelial neoplastic (PIN) lesions that progress to metastatic disease (BMPC mice). Yet, single gene alterations in these mice result only in PIN lesions. In this study, we performed transcriptomic profiling of PIN lesions from each of the three genotypes. Whereas MYC alone resulted in increases in genes related to cell-cycle regulation/cell division, combined MYC and Pten loss led to a further and more consistent increase and a synergistic cell-cycle progression. Increased ribosome biogenesis/translation is required for cell proliferation. Whereas MYC alone increased 45S rRNA and most components of the translation machinery, these were more strongly induced in BMPC mice. Surprisingly, Pten loss alone resulted in a downregulation of translation machinery genes, which could explain the absence of biallelic PTEN loss in human PIN lesions and early carcinomas. Some MYC targets were increased only after Pten loss, indicating Pten loss increases MYC activity. Implications: Increased cell cycle and translational machinery gene induction may explain the synergy between MYC and PTEN loss for increasing prostate cancer cell proliferation and disease aggressiveness. These results provide further support for the therapeutic targeting of translation in prostate cancer.
Year:
2025
Provirus integration site for Moloney murine leukemia virus (PIM) family serine/threonine kinases perform protumorigenic functions in hematologic malignancies and solid tumors by phosphorylating substrates involved in tumor metabolism, cell survival, metastasis, inflammation, and immune cell invasion. However, a comprehensive understanding of PIM kinase functions is currently lacking. Multiple small-molecule PIM kinase inhibitors are currently being evaluated as cotherapeutics in patients with cancer. To further illuminate PIM kinase functions in cancer, we deeply profiled PIM1 substrates using the reverse in-gel kinase assay to identify downstream cellular processes targetable with small molecules. Pathway analyses of putative PIM substrates nominated RNA splicing and ribosomal RNA (rRNA) processing as PIM-regulated cellular processes. PIM inhibition elicited reproducible splicing changes in PIM-inhibitor–responsive acute myeloid leukemia (AML) cell lines. PIM inhibitors synergized with splicing modulators targeting splicing factor 3b subunit 1 (SF3B1) and serine-arginine protein kinase 1 (SRPK1) to kill AML cells. PIM inhibition also altered rRNA processing, and PIM inhibitors synergized with an RNA polymerase I inhibitor to kill AML cells and block AML tumor growth. These data demonstrate that deep kinase substrate knowledge can illuminate unappreciated kinase functions, nominating synergistic cotherapeutic strategies. This approach may expand the cotherapeutic armamentarium to overcome kinase inhibitor–resistant disease that limits durable responses in malignant disease.
Year:
2024
Year:
2021
Collaborators (3)
Srinivasan Yegnasubramanian
-
Seungchul Baek
University of Maryland Baltimore County
Angelo De Marzo
Professor
Johns Hopkins University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.